DCPH News and Press, Deciphera Pharmaceuticals Inc. From 07/11/21

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

– Phase 1 Study will Assess First-in-Class Switch-control ULK Kinase Inhibitor Designed to Inhibit Autophagy as a Single Agent and in Combination with a MEK Inhibitor – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical...

Deciphera Pharmaceuticals ([[DCPH]] -0.5%) posts data from the company's late-stage INVICTUS study of QINLOCK in patients with advanced gastrointestinal stromal tumor ((GIST)), as well as preliminary results from its Phase 1b/2 study of rebastinib in combination with paclitaxel in patien...

– Exploratory Analysis of the INVICTUS Phase 3 Study Showed QINLOCK Dose Escalation After Disease Progression Provided Substantial Clinical Benefit in Advanced GIST – – Rebastinib in Combination with Paclitaxel in a Phase 1b/2 Study Demonstrate...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) are trading close to a 52-week low of $33.55 -- pretty far from the $57.89 they commanded last year at this time. The company, which went public with an IPO in 2017, got a big bump late in 2019 on positive phase 3 trials for its...

Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2021 Earnings Conference Call May 4, 2021 16:30 ET Company Participants Jen Robinson - Vice President, Investor Relations Steven Hoerter - President & Chief Executive Officer Daniel Martin - Chief Commercial Officer Matthew Sherman - Chief Medical...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Q1 2021 Earnings Call May 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2021 Earnings Call...

Deciphera Pharmaceuticals (DCPH): Q1 GAAP EPS of -$1.06 beats by $0.01.Revenue of $25.2M, beats by $2.15M.Press Release For further details see: Deciphera Pharmaceuticals EPS beats by $0.01, beats on revenue

- First Quarter 2021 QINLOCK® Net Product Revenue of $20.0 Million; QINLOCK Approved in China and Hong Kong for Fourth-line GIST - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Fourth Quarter of 2021; Plans to ...